Cogent Biosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Cogent is a clinical-stage biotechnology company developing precision therapies; it had no approved products and reported no product revenue.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue from product sales | None reported | None reported | None reported | None reported |
| Research and development expense | $38.9 million | $29.5 million | $74.9 million | $54.9 million |
| General and administrative expense | $8.2 million | $6.4 million | $15.4 million | $12.3 million |
| Total operating expenses | $47.1 million | $35.9 million | $90.3 million | $67.3 million |
| Net loss | $44.1 million | $34.9 million | $82.7 million | $65.6 million |
| Net loss per share | $0.59 | $0.71 | $1.14 | $1.39 |
- There are no meaningful revenue or profit margins to assess given the absence of product sales and recurring operating losses.
- For the six months, operating cash use was $71.6 million, compared with $54.8 million in 2022. Investing activities used $17.8 million; financing provided $162.5 million, primarily from the June stock offering.
- At June 30, cash and cash equivalents were $214.3 million and marketable securities totaled $136.6 million, for combined liquidity of $350.9 million. Current assets were $334.5 million and current liabilities $25.8 million.
- The filing reports no borrowings; liabilities were primarily operating lease obligations and accrued expenses. Accumulated deficit was $493.9 million.
Changes versus comparable periods
- Q2 net loss increased $9.1 million year over year; six-month net loss increased $17.1 million. Higher clinical and research activity, pipeline development, headcount, stock-based compensation, and laboratory and facility costs drove expense growth.
- Six-month R&D expense increased $20.0 million, including increased bezuclastinib trial and manufacturing costs and preclinical research spending. G&A increased $3.1 million.
- Interest income rose to $5.0 million for the first half from $0.4 million, reflecting higher invested balances. A $1.7 million noncash gain from reducing the CVR liability to zero partially offset the higher operating loss.
- In June, Cogent raised approximately $161.8 million net through an underwritten offering of 14.375 million common shares. Common shares outstanding rose to 85.3 million from 69.9 million at December 31, 2022. As-converted shares, including preferred stock and remaining pre-funded warrants, were 105.2 million at June 30.
Outlook, operations, and risks
- Management expects current cash, cash equivalents, and marketable securities to fund operating and capital requirements into 2026, based on current plans and assumptions. The filing also states the company will require additional funding to complete planned activities and may seek equity, debt, collaboration, licensing, or other arrangements.
- Bezuclastinib is the most advanced program, being studied in systemic mastocytosis and GIST. Management expected APEX Part 1 data from approximately 30 patients and initial SUMMIT data in the second half of 2023. The PEAK Phase 3 trial is evaluating bezuclastinib plus sunitinib versus sunitinib alone; reported lead-in data were described as encouraging, but were immature for estimating median progression-free survival.
- Cogent has selected an FGFR2 clinical candidate and expected to announce an ErbB2 candidate in 2024. These programs remain in development, and clinical benefit is not established by the filing.
- Key risks include clinical trial results, safety and enrollment, regulatory outcomes, manufacturing and supply, competition, intellectual-property protection, and the need for additional capital. Financing could dilute shareholders or require the company to surrender rights.
- The CVR liability was reduced to zero in Q1 2023; the CVRs expired August 6, 2023, with no further payments expected. The company reported no material legal proceedings and no material changes to the risk factors in its prior Form 10-K.
- No formal financial guidance was provided. Management cautions that runway estimates and development timelines depend on assumptions and may change.
Investor verification priorities
- Check subsequent filings and company updates for APEX and SUMMIT data, trial enrollment, safety, and the timing and progress of PEAK.
- Assess cash burn against the stated runway into 2026, including the costs of trials, manufacturing, and expanding research programs.
- Review dilution exposure: common shares outstanding, 19.3 million shares issuable upon conversion of Series A preferred stock, outstanding pre-funded warrants, and equity awards.
- Confirm whether development milestones, regulatory plans, or financing needs have changed, and review the terms of any new funding or collaboration arrangements.
- Evaluate the evidence supporting pipeline claims and the remaining clinical, regulatory, commercial, and intellectual-property risks.